Tests TUB-040 in adults with ovarian or lung cancer that resisted or returned
Tests TUB-040, a new drug, in adults with ovarian or lung cancer.
Key facts
- Who runs it
- Gilead Sciences
- Where
- London, United KingdomSee the siteAlso in 6 other countries, 34 sites
- Trial code
- Registry title
- FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 334 people, planned
- Started
- 12 Jun 2024
- Expected to end
- Dec 2027
- Type of study
- Interventional, 5 groups
- Treatments tested
- TUB-040
- Bevacizumab
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with platinum-resistant high-grade ovarian cancer or relapsed or treatment-resistant adenocarcinoma lung cancer (NSCLC), whose disease cannot be treated with treatment meant to remove all of it and who have used up standard treatments.
- Age
- 18 years or older
- Sex
- All sexes can join. Pregnant or breastfeeding women cannot join.
- Disease stage
- Ovarian or lung cancer that cannot be treated with treatment meant to remove all of the disease. The disease must be measurable on scans (RECIST 1.1). Good daily function (ECOG 0-1) and life expectancy of more than 12 weeks.
- Earlier treatment
- Standard treatments that help survival must be used up. Earlier topoisomerase I inhibitor treatment (for example Topotecan) is allowed. No other anti-cancer treatment, no trial drug in the last 28 days, no live vaccine in the last 30 days.
- Biomarker or test result
- Tumour tissue stored from before must be available for testing marker levels. No other specific marker is stated.
Main reasons for not taking part
- Pregnant or breastfeeding
- Allergy to exatecan or to the ingredients of TUB-040
- Past or current lung inflammation (ILD or pneumonitis)
- Active brain or spinal cord disease, or cancer in the membranes around the brain
- Active corneal disease, or corneal disease in the last 12 months
The registry criteria, word for word
Show all 33 criteriaShow less
Who can take part
- Male or non-pregnant, non-breastfeeding female, age 18 years or older at the date of consent
- Disease not amenable to curative intent treatment
- Individuals have exhausted the standard of care treatment (SoC) with expected survival benefit and are not denied SoC with expected survival benefit by participating in the trial
- Individuals with previous systemic topoisomerase I inhibitor treatment (e.g., Topotecan) are allowed in the study
- Radiologically measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by the INV
- Eastern Cooperative Oncology Group (ECOG) 0-1
- Have a life expectancy of more than 12 weeks for disease-related mortality, as evaluated by the INV
- Individuals must be willing to sign an archival tissue release form for research purposes and determination of biomarker expression
- Individuals must be willing to undergo a non-contrast high resolution computed tomography (HRCT) of the thorax scan and pulmonary function testing (PFT) at screening
- Adequate organ function
- Resolution of all acute toxic effects of prior therapy or surgical procedures to ≤grade 1 (except alopecia, hyperpigmentation, or discoloration (incl. vitiligo) of the skin and nails, stable immune-related toxicity such as hypothyroidism on hormone replacement, adrenal insufficiency on ≤10 mg daily prednisone [or equivalent], chronic grade 2 peripheral sensory neuropathy after prior taxane therapy or anticancer treatment such as but not limited to immune oncology therapy (IOs))
- Individuals of childbearing potential (FCBP) who are sexually active with a non-sterilized partner must use at least one highly effective method of contraception from the time of screening and must agree to continue using such precautions until the end of exposure, plus 5 half-lives and 6 months add-on in the case of individuals assigned female at birth
- In the opinion of the investigator, the individual must be able to understand, give written informed consent, and comply with all study-related procedures, medication use, and evaluations
- The individual must not have a history of non-compliance with medical regimens or be considered potentially unreliable and/or uncooperative
- The individual must be willing to sign and date the informed consent form (ICF)
Who cannot take part
- Individuals are not allowed to participate in interventional clinical studies either concurrently or within the previous 28 days or within 5 half-lives of any investigational pharmacologic agents or imaging materials, including dyes, investigational surgical techniques, or devices
- Prior radiotherapy <2 weeks from trial inclusion
- Major surgery within 21 days prior to signing the ICF, unless the individual is recovered at that time
- Active corneal disease, or history of corneal disease within 12 months prior to enrollment
- Documented other concurrent non-malignant comorbidities such as unstable or uncontrolled pectoral angina, myocardial infarction during the last 6 months, valvular heart disease that requires treatment, acute myocarditis, or congestive heart failure (CHF) (New York Heart Association III or IV)
- Concurrent use of strong inhibitors or strong inducers of CYP3A4
- Live vaccines within 30 days prior to study entry
- Individuals with acute or chronic infections such as:; Individuals who are HBsAg positive are eligible if they have received Hepatitis B virus (HBV) anti-viral therapy for at least 4 weeks and have an undetectable HBV viral load prior to randomization; Individuals with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening; HIV infected individuals must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease; Any other known unresolved and active bacterial, viral, fungal, mycobacterial, or other infection at screening; History of severe and recurrent infections per INV judgment; History of progressive multifocal leukoencephalopathy; Note: Other protocol defined Inclusion/Exclusion criteria may apply
- History of hypersensitivity to exatecan or excipients of the TUB-040 formulation
- Individuals with spinal cord compression or active central nervous system disease, and/or carcinomatous meningitis
- Has a history of non-infectious interstitial lung disease/pneumonitis (ILD)/pneumonitis/radiation pneumonitis that required steroids or has current ILD/pneumonitis
- History of nephrotic syndrome
- Active, uncontrolled or severe impairment of the urogenital, renal, hepatobiliary, cardiovascular, gastrointestinal, neurologic, or hematopoietic systems which, in the opinion of the investigator, would predispose the individual to the development of complications from the administration of protocol therapy
- History of another malignancy with ongoing treatment or not yet free from disease for 2 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or other malignancy with a similar expected curative outcome
- Any anti-tumor chemotherapy, systemic anti-cancer therapy, radiotherapy (except for local radiation therapy of lesions that may cause imminent complications), hormonal therapy, immunotherapy, or corticoid therapy
- The individual is pregnant, lactating or breastfeeding or has a positive serum pregnancy test during the screening period
- Has an oxygen saturation of <93% on room air at rest
- Has a QTcF >470 ms
Where in United Kingdom
Also in 6 other countries, 34 sites
- Guy's HospitalLondon, United KingdomNo longer taking part
About the trial
What the trial wants to find out
The goal of this clinical study is to learn more about the study drug, TUB-040, including its safety, tolerability, pharmacokinetics, and preliminary efficacy, and to determine the best dose of TUB-040 in participants with ovarian cancer or non-small cell lung cancer (NSCLC).
Read full original descriptionShow less
The primary objectives of this study are:
Phase 1: To determine the safety and tolerability of TUB-040 and determine the maximum tolerated dose (MTD) or the identified dose for optimization (IDO).
Phase 2a: To assess safety of TUB-040, the preliminary efficacy of TUB-040, and to identify the recommended phase II dose (RP2D) for further development of TUB-040 .
Phase 2b: To determine the efficacy of TUB-040 in patients with PROC.
The 5 groups in the trial
- Phase 1: Cohort 1: Dose Escalation in Platinum Resistant Ovarian Cancer (PROC)Treatment being tested
Participants will receive escalating doses of TUB-040 every 3 weeks until the disease progresses or the patient has to stop due to side effects.
Treatment: TUB-040
- Phase 1: Cohort 2: Dose Escalation in R/R NSCLC of the adenocarcinoma subtypeTreatment being tested
Participants will receive escalating doses of TUB-040 every 3 weeks until the disease progresses or the patient has to stop due to side effects.
Treatment: TUB-040
- Phase 1: Cohort 3: PROC, Combination with Bevacizumab (BEV)Treatment being tested
Participants will receive escalating doses of TUB-040 combined with BEV every 3 weeks until the disease progresses or the patient has to stop due to side effects.
Treatment: TUB-040 and Bevacizumab
- Phase 2a: Dose Optimization in PROCTreatment being tested
Participants will receive two different dose levels of TUB-040 every 3 weeks until the disease progresses or the patient has to stop due to side effects.
Treatment: TUB-040
- Phase 2b: Dose Expansion in PROCTreatment being tested
Patients will receive TUB-040 at the safe dose established during dose escalation until disease progression or unacceptable toxicity.
Treatment: TUB-040
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Multicenter, First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients With Platinum-resistant High-grade Ovarian Cancer (PROC) or r/r Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)
- Plain-language title
- Tests TUB-040 in adults with ovarian or lung cancer that resisted or returnedGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 3 November 2026